NTHL1 is a recessive cancer susceptibility gene

Anna Nurmi(University of Helsinki), Tarja Laitinen(Tampere University), Jaakko Kaprio(University of Helsinki), Robert Graham(GenProMarkers (United States)), Anne Pitkäranta, Antti Hakanen, Jukka Partanen(Finnish Red Cross), Jani T. Tikkanen(University of Oulu), George Okafo, Dirk S. Paul(AstraZeneca (United Kingdom)), Maija T. Suvanto(University of Helsinki), Simonne Longerich, Anders Mälarstig(Karolinska Institutet), Anne Kallioniemi(University of California, San Francisco), Päivi Heikkilä(University of Helsinki), Bridget Riley‐Gillis(AbbVie (United States)), Tomi P. Mäkelä(University of Helsinki), Liisa M. Pelttari(University of Helsinki), Markus Perola(Broad Institute), Sofia Khan(University of Helsinki), Tiina Tasmuth(University of Helsinki), Mark I. McCarthy(Centre for Human Genetics), Raisa Serpi, Matthias Gossel, Howard J. Jacob(Medical College of Wisconsin), Johanna Schleutker(University of Turku), Terhi Kilpi(Finnish Institute for Health and Welfare), Taneli Raivio(University of Helsinki), Eija Kalso(Helsinki Art Museum), Margaret G. Ehm(GlaxoSmithKline (United States)), Aarno Palotie(Broad Institute), Heiko Runz(Heidelberg University), Joseph Maranville(Finnish Institute for Health and Welfare), Mika Nurmikolu(University of Helsinki), Niina Aho(University of Helsinki), Johanna I. Kiiski(University of Helsinki), Clément Chatelain, Slavé Petrovski(AstraZeneca (United Kingdom)), Robert M. Plenge, Mark J. Daly(Broad Institute), Robert Yang, Sally John, Petri Virolainen, Kirsi Auro(University of Helsinki), Heli Salminen‐Mankonen, K. Klinger(Sanofi (France)), Karol Estrada(Erasmus MC), Chris O’Donnell(Victorian Institute of Forensic Medicine), Nathan Lawless
Scientific Reports
November 30, 2023
Cited by 10


Related Papers